INVEST IN EO2 CONCEPTS TODAY!
Oxygen-Enhanced Technology for Advanced Wound Healing and Skin Support
$697,864.62 Raised
REASONS TO INVEST
EO2’s CDO therapy system is an enhanced wound care solution that improves patient outcomes when recovering from chronic wounds, skin injuries, or surgeries. It utilizes the continuous delivery of oxygen directly to the tissue, which has been shown to achieve faster healing, reduced pain levels, and overall improved skin health.*
EO2’s addressable market encompasses two multibillion dollar divisions. Globally, the chronic wound care sector is estimated to be worth over $20B,*while the aesthetics and cosmetic surgery industry is valued at $63.4B and expected to exhibit nearly double digit CAGR between now and 2030.*
As an industry innovator, EO2 is focused on continual product testing, research, development, and design, in collaboration with key opinion leaders and medical professionals. Our unique position in an expanding marketplace is secure through 2038, protected by numerous national and international patents, as well as additional patents pending.
*Market information provided by (source) (source) (source)
overview
Advanced Wound Care Therapy Powered By Pure Oxygen
For patients recovering from wounds (i.e. ulcers and burns), amputations, and cosmetic/restorative surgeries, oxygen is one of the most vital elements in the wound-healing process (source). Understanding this, EO2 has developed proprietary technology that allows pure, humidified oxygen to be continuously diffused directly into the tissue, thereby creating an optimal environment for skin repair and restoration. The OxyGeni is an all-inclusive system that offers oxygen generation, wound monitoring, oxygen diffusion dressings, and accessories, all in one lightweight and discrete wearable device.
The Problem & Our Solution
Making CDO Therapy Accessible To Support Wound Healing 24/7
A common obstacle to proper healing of wounds is a lack of oxygen, caused by blocked or damaged blood pathways. Oxygen via the bloodstream is what provides nourishment to the skin and dermal tissues, fueling important processes like collagen formation, cellular regeneration, antibacterial activity, and repair. When the body doesn’t have access to sufficient levels of oxygen, it becomes much harder to carry out these essential functions. However, most existing wound care options involve covering damaged skin, thereby blocking direct flow of oxygen to the tissue.
As a solution, EO2 has developed a system that not only restores oxygen levels, yet also enhances those levels beyond the body’s normal capacity. Using our wearable device, patients receive advanced wound care anywhere, anytime, and are able to accelerate the entire healing process. Additionally, because CDO therapy has benefits for reducing pain and inhibiting the formation of scars, the technology helps to restore quality of life. Positive outcomes from treatment with OxyGeni range from improving aesthetic appearance to preventing amputation.
The Market & Our Traction
Building a Science-Backed Brand That’s Responsive To An Evolving Market
Over the last several years, EO2 has been making significant progress across many verticals. In clinical trials, the company’s technology has been substantiated by multiple studies, with peer-reviewed papers published by notable national and international industry leaders. Meanwhile, on the marketing side, we’ve seen mass social media response to the performance of our products for patients, especially in the cosmetic procedures market.
As a result of our success in these areas, EO2 has seen a robust increase in sales. Within the plastics and aesthetics market, we’ve demonstrated triple-digit YOY growth and in Canada, the company has moved from unpaid trials to payment models in six provinces. By creating products designed to accommodate today’s telehealth models, we are enabling patients to be more involved in their own care through mobile app design, automated product delivery, and AI-driven communication.
Although EO2 Concepts initially developed solutions for the chronic wound care market, the company has exciting opportunities to expand into other markets based on the science of oxygen therapy’s efficacy and the feedback of medical users. Our newest and fastest-growing market is in aesthetic and reconstructive surgery, as the technology can be used to facilitate healing following face lifts, breast reductions, laser facials, and cosmetic injectables.
Why Invest
Invest in Proven Technology That Helps People Heal
Chronic wounds affect millions of patients each year and the costs to our healthcare system for diabetic foot complications alone are comparable to all cancers combined (source). Complications from a wound can last months or years, sometimes resulting in amputations, and severely impacting quality of life for patients. Having developed a system that can improve recovery outcomes, in a more accessible and affordable format, EO2’s vision is to bring our technology to the medical community and become the standard of care across multiple segments. Be a part of our success story by investing on Start Engine!
ABOUT
HEADQUARTERS
12500 Network Blvd Ste 310
San Antonio, TX 78249
WEBSITE
View Site
EO2 Concepts is an advanced wound healing technology company leveraging continuous diffusion of oxygen (CDO) therapy to commercialize innovative medical modalities. The company’s primary in-market product is OxyGeni, a wearable device designed to heal wounds to complete closure while simultaneously supporting skin and soft tissue restoration, shortening recovery time, reducing pain, and minimizing the formation of scar tissue in the process.
TEAM
Mark Niederauer
President, CEO, Board Member
Ken Melani, MD
Board member
Dave Kazynski
Exec. VP of Sales and Marketing, Board Member
Peter Smith
Chairman of the Board of Directors
Jim DeYoung
Board Member
Justin Cypert
Controller
James P. Daley
Director of Operations
Cyndi Gilliam, BSN, RN, FACCWS
Director of Clinical Affairs
Kate Biasiolli
Marketing Manager
Joseph Monosmith
Quality Assurance Manager
TERMS
EO2 Concepts
Overview
PRICE PER SHARE
$1.59
DEADLINE
Jun 30, 2023
VALUATION
$78.44M
FUNDING GOAL
$15k - $1.23M
Breakdown
MIN INVESTMENT
$298.92
MAX INVESTMENT
$1,234,997.52
MIN NUMBER OF SHARES OFFERED
9,433
MAX NUMBER OF SHARES OFFERED
776,728
OFFERING TYPE
Equity
ASSET TYPE
Preferred Stock
SHARES OFFERED
Series A Preferred Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Time Based Perks
o First 72 hours – 10% Super Early Bird Bonus
o First week (days 4-7) – 8% Very Early Bird Bonus
o First 3 weeks (week 2 & 3) - 5% Early Bird Bonus
Amount Based Perks
o $600+ – 3% bonus shares , Member, Contributing to enabling advanced healing with oxygen.
o $1,500+ – 5% bonus shares, Leader, Leading the way in oxygen healing solutions.
o $5,000+ – 8% bonus shares, Innovator, Bringing next generation solutions to oxygen delivery and patient monitoring.
o $15,000+ – 10% bonus shares, Visionary, Ensuring the long-term growth and innovation in oxygen solutions for health care.
Loyalty Bonus - 10% Bonus Shares for Friends and Family
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Electrochemical Oxygen Concepts, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A Non-Voting Preferred Stock at $1.59/ share, you will receive 110 shares of Series A Non-Voting Preferred Stock, meaning you'll own 110 shares for $159. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and an the Loyalty bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company will not incur irregular use of proceeds.
NEW UPDATES
06.06.23
NEW Registered Trademark for CDO in the UK!
EO2 is pleased to announce issuance of a certificate of registration for the United Kingdom Trademark to add to their robust portfolio. The UK recently issued patent No. UK00003881009, in International Class 10, covering “Medical devices, namely, portable low-dose tissue oxygenation units for promoting wound healing, sold as unit with medical tubing and parts and accessories thereof.” CDO will now be under trademark protection until 2033.
Click the link to learn more and join us! - https://investment.startengine.com/eo2
06.05.23
EO2 Welcomes New CFO!
EO2 is excited to welcome Anthony (Tony) Gallardo to the team as the new Chief Financial Officer. After earning his Bachelors degree in accounting from the University of Texas at San Antonio, Tony has been a Certified Public Accountant with over 30 years of financial and operational experience. Tony has worked as COO and CFO for entrepreneurial companies in home health care and mental health. With over 30 years of experience Tony is adept at improving processes, including financial reporting, cash flow, internal controls and compliance with contract and regulatory requirements.
As a financial leader Tony has extensive experience with budgeting and forecasting. He has guided operational teams to successfully prepare and exceed budgets. Additionally, over his career he has successfully guided the accounting team to set up the internal controls and processes for high growth companies.
We are excited for this new addition to our EO2 team and looking forward to good things to come.
Click the link to learn more and join us! - https://investment.startengine.com/eo2
PRESS
ALL UPDATES
06.02.23
Join us in Redefining the Speed & Comfort of Wound Care
Our next stage of growth includes expanding our sales and inventory to reach new markets and developing our smart phone apps to connect to the cloud, allowing patients to track their healing process, similar to a Fitbit. Also allowing doctors and nurses to remotely interact with their patients. Join us in redefining the speed and comfort of wound care.
Click the link to learn more and join us! - https://www.startengine.com/offering/eo2
05.19.23
NEW Revolutionary Dressing Design for Cosmetic Surgery!
We are proud to announce the launch of our latest product, a revolutionary dressing design within our CDO portfolio. We are rapidly making a mark within the $63 billion plastics and cosmetic surgery industry, seeing explosive growth thanks to our focus on meeting the needs of early adopters. Our dedicated engineering team has worked closely with top thought leaders in this field to develop a dressing design that seamlessly integrates into their practices. The 2x10 dressing design has been specifically created to provide the necessary oxygen to decrease pain levels and accelerate the healing process for incision lines resulting from procedures such as tummy tucks and breast augmentations. We invite you to join us on our journey towards innovation and success within this exciting industry.
Click the link to learn more and join us! - https://www.startengine.com/offering/eo2
05.16.23
$63.4B Aesthetics Industry Expected to Exhibit Nearly Double Digit CAGR by 2030!
EO2’s addressable market encompasses two multibillion dollar divisions. One of those is the aesthetics and cosmetic surgery industry is valued at $63.4B and expected to exhibit nearly double digit CAGR between now and 2030. Join us in expanding our influence in this rapidly growing market.
Click the link to learn more and join us! - https://www.startengine.com/offering/eo2
05.10.23
600K Fundraising Milestone Reached!
Another fundraising milestone met this week!
We have now passed $600k and are approaching $650k. If you haven’t had a chance, please take a moment to check out our investment opportunity on StartEngine.
Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2
05.05.23
EO2 Welcomes New Board Member
We are pleased to welcome our newest board member Ken Melani, MD!
Dr. Melani is currently the owner of KRM Group LLC, a healthcare consulting firm, and managing director of Velocity Fund Partners LLC, a life sciences venture capital fund. He started his career as a practicing Internist where he founded and later became Chairman and CEO of a physician-hospital organization called West Penn Cares. Over the next twenty-five years he served in a variety of executive leadership roles at Highmark Inc, culminating as the President and CEO. He is credited with growing Highmark into one of the leading healthcare companies in the United States and is personally regarded as one of the top healthcare executives in the country. Dr. Melani received his BA from Washington and Jefferson College, where he graduated Summa Cum Laude, and went on to receive a Doctorate of Medicine from The Wake Forest University School of Medicine.
Interested in learning more about our team? Click the link below to learn more and join us! - https://www.startengine.com/offering/eo2
05.02.23
EO2: A Breath of Fresh Air in the World of Wound Care
Are you tired of hearing the same old puns in the medical industry? Then get ready for a breath of fresh air with EO2. With its CDO therapy system, EO2 is revolutionizing wound care with the power of oxygen. But it's not just about the puns - EO2 is serious about promoting faster healing, reducing pain levels, and improving overall skin health. And with a commitment to continual product testing, research, development, and design, EO2 is always looking for ways to stay ahead of the game. So whether you're a medical professional or just a fan of a good pun, check out EO2 and discover the power of oxygen in wound care.
Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2
04.28.23
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the EO2 Concepts offering. Here's an excerpt describing the specifics of the change:
EO2 Concepts extending their campaign end date and updated their financials
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
04.24.23
EO2 Announces New Patent
EO2 is pleased to announce the issuance of another patent to add to their robust patent portfolio. Canada recently issued patent number 3005473 for EO2’s proprietary and novel CDO System for enhancing tissue oxygenation using smart sensors to detect conditions in the wound bed. This allows for real-time control and monitoring of patient care in a remote setting.
Learn more and join us at: https://www.startengine.com/offering/eo2
04.21.23
EO2 - The Best Thing to Happen to Wounds Since the Invention of Band-Aids
From the creators of "Air You Can Wear" comes EO2's CDO therapy system - the ultimate wound care solution. Using the power of oxygen, EO2's innovative therapy system promotes faster healing, reduced pain levels, and overall improved skin health. Say goodbye to slow healing times and hello to a bright future with EO2. Join the revolution and invest in a company that is the best thing to happen to wounds since the invention of Band-Aids.
Read more details and join us at: https://www.startengine.com/offering/eo2
04.19.23
Join the Revolution in Wound Care with EO2
With EO2's innovative CDO therapy system, the game is changing in wound care. By delivering oxygen therapy directly to the tissue, EO2's system promotes faster healing, reduces pain levels, and overall improves skin health. The wound care sector is estimated to be worth over $20B globally, and with EO2's unique solution, investors have the opportunity to participate in an expanding marketplace while making a difference in patient care.
Learn more and join us at: https://www.startengine.com/offering/eo2
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
$298
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$600
Member
Invest $600+ and receive 3% Bonus shares
$1,500
Leader
Invest $1,500+ and receive 5% Bonus shares
$5,000
Innovator
Invest $5,000+ and receive 8% Bonus shares
$15,000
Visionary
Invest $15,000+ and receive 10% Bonus Shares
JOIN THE DISCUSSION
0/2500
Christopher Lill
17 INVESTMENTS
8 days ago
Hello, I would like to know more about your patents ie how many you have and how many pending? Th×
2
0
Stephen Hart
10 INVESTMENTS
a month ago
Is this system available now?
4
0
Terry Dew
2 months ago
What differentiates you from other similar units on the market?
1
0
Michael Myers
2 months ago
Exciting technology, I work in the DME industry and have dealt w/NPWT which is a pain both for the patient and the DME, would be interested in considering this as a new product line, especially w/cash options to plastic/reconstructive surgery being a potential customer.
1
0
Joseph Russo
2 months ago
This really interested me. As my mother in law had her feet slowly taken off but by bit because she could not heal the area. This would have save her life because she would not have suken into a deep depression that she never came out of. I believe this will save more then time and money in medical costs but the mental health issues related to wounds that don’t heal.
1
0
Ronnie Jaikaran
3 months ago
Hello.
Is there any tax documents that I need from you for my 2022 filing? Start-up investing is all new to me.
1
0
Addison Delk
1 INVESTMENTS
6 months ago
What is your current revenue?
How did you get to a $78m valuation?
1
0
Russell Smith
9 INVESTMENTS
7 months ago
Exciting stuff for sure - i wonder if you can further detail where you are in the revenue and expansion cycle ? - you mentioned moving from free to paid in 6 Canadian provinces, but what is happening in the US and other areas ? what state are the finances in currently and what would next steps and use-of-funds be used-for please ? sorry for the questions, but interested in the tech....thanks
1
1
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
W Kim Colich
87 INVESTMENTS
4 days ago
0
0